http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3271399-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ffd5528fd07384d7b07ab484ed5b143 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate | 2016-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7add44b1035a9f2fe90c15dbfc409503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e57d55d90bcea52d6fc7d2b043b72dba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_886019f06a0a6a13737bb2193326ee59 |
| publicationDate | 2018-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3271399-A2 |
| titleOfInvention | Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies |
| abstract | Provided are compositions and methods for the treatment of hematological conditions, in particular haematopoietic and lymphoid malignancies including CD99+ acute myelogenous leukemias (AML), myelodysplasia syndromes (MDS) and T-cell neoplasms, which comprise one or more antibody that (a) binds to the extracellular domain of CD99, (b) ligates myeloid or lymphoid malignant cell-surface expressed CD99, (c) promotes the capping/clustering/aggregation myeloid or lymphoid malignant cell-surface expressed CD99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated CD99+ myeloid or lymphoid malignant cells. Disclosed methods include methods for identifying patients afflicted with a haematopoietic or lymphoid malignancy that are susceptible to treatment with an anti- CD99 antibody by detecting the elevated expression of CD99 in a tissue sample or myeloid or lymphoid malignant cell from a patient and for treating a patient afflicted with a haematopoietic or lymphoid malignancy exhibiting elevated CD99 gene and or cell-surface protein expression by administering a composition comprising an anti-CD99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and a chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5- azacytidine, and decitabine. |
| priorityDate | 2015-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 849.